136 related articles for article (PubMed ID: 20040336)
1. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.
Nakamuta M; Fujino T; Yada R; Yasutake K; Yoshimoto T; Harada N; Yada M; Higuchi N; Kato M; Kohjima M; Taketomi A; Maehara Y; Nishinakagawa T; Machida K; Matsunaga K; Nakashima M; Kotoh K; Enjoji M
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):22-8. PubMed ID: 20040336
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.
Kita R; Takamatsu S; Kimura T; Kokuryu H; Osaki Y; Tomono N
J Gastroenterol; 2006 Jul; 41(7):686-92. PubMed ID: 16933007
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.
Ghonem NS; Ananthanarayanan M; Soroka CJ; Boyer JL
Hepatology; 2014 Mar; 59(3):1030-42. PubMed ID: 24122873
[TBL] [Abstract][Full Text] [Related]
4. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis.
Akbar SM; Furukawa S; Nakanishi S; Abe M; Horiike N; Onji M
J Gastroenterol; 2005 Feb; 40(2):157-63. PubMed ID: 15770399
[TBL] [Abstract][Full Text] [Related]
6. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Dohmen K; Tanaka H; Haruno M
Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
[TBL] [Abstract][Full Text] [Related]
8. Bezafibrate for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Jan; 1():CD009145. PubMed ID: 22259000
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation.
Hidaka M; Iwasaki S; Matsui T; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Kiyokawa T; Takahashi M; Saibara T; Onishi S; Kawano F
Bone Marrow Transplant; 2010 May; 45(5):912-8. PubMed ID: 19802024
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4.
Shoda J; Inada Y; Tsuji A; Kusama H; Ueda T; Ikegami T; Suzuki H; Sugiyama Y; Cohen DE; Tanaka N
J Lipid Res; 2004 Oct; 45(10):1813-25. PubMed ID: 15258199
[TBL] [Abstract][Full Text] [Related]
11. Effect of bezafibrate in primary biliary cirrhosis: a pilot study.
Ohmoto K; Mitsui Y; Yamamoto S
Liver; 2001 Jun; 21(3):223-4. PubMed ID: 11422787
[No Abstract] [Full Text] [Related]
12. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
Lens S; Leoz M; Nazal L; Bruguera M; Parés A
Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489
[TBL] [Abstract][Full Text] [Related]
13. Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice.
Shoda J; Okada K; Inada Y; Kusama H; Utsunomiya H; Oda K; Yokoi T; Yoshizato K; Suzuki H
Hepatol Res; 2007 Jul; 37(7):548-56. PubMed ID: 17539998
[TBL] [Abstract][Full Text] [Related]
14. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
15. Bezafibrate for the treatment of primary sclerosing cholangitis.
Mizuno S; Hirano K; Tada M; Yamamoto K; Yashima Y; Yagioka H; Kawakubo K; Ito Y; Kogure H; Sasaki T; Arizumi T; Togawa O; Matsubara S; Nakai Y; Sasahira N; Tsujino T; Isayama H; Kawabe T; Omata M; Koike K
J Gastroenterol; 2010 Jul; 45(7):758-62. PubMed ID: 20127368
[TBL] [Abstract][Full Text] [Related]
16. Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat.
Kamisako T; Ogawa H
J Gastroenterol Hepatol; 2004 Aug; 19(8):879-83. PubMed ID: 15242490
[TBL] [Abstract][Full Text] [Related]
17. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
Chianale J; Vollrath V; Wielandt AM; Amigo L; Rigotti A; Nervi F; Gonzalez S; Andrade L; Pizarro M; Accatino L
Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):781-6. PubMed ID: 8615769
[TBL] [Abstract][Full Text] [Related]
18. Elevated hepatic MDR3/ABCB4 is directly mediated by MiR-378a-5p in human obstructive cholestasis.
Song CW; Qiu W; Zhou XQ; Feng XC; Chen WS
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2539-2547. PubMed ID: 30964181
[TBL] [Abstract][Full Text] [Related]
19. A novel treatment for refractory primary biliary cirrhosis?
Miyaguchi S; Ebinuma H; Imaeda H; Nitta Y; Watanabe T; Saito H; Ishii H
Hepatogastroenterology; 2000; 47(36):1518-21. PubMed ID: 11148991
[TBL] [Abstract][Full Text] [Related]
20. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.
Zollner G; Fickert P; Zenz R; Fuchsbichler A; Stumptner C; Kenner L; Ferenci P; Stauber RE; Krejs GJ; Denk H; Zatloukal K; Trauner M
Hepatology; 2001 Mar; 33(3):633-46. PubMed ID: 11230744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
